Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2024-01-08 00:00:00 ET · period of report 2023-11-04 · accession 0001209191-24-001155 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-08 | 2023-11-04 | KROS | Regnante Keith | CFO | M - OptEx | $16.00 | +40.0K | 40.0K | New | +$640.0K |
| D | 2024-01-08 | 2023-11-04 | KROS | Regnante Keith | CFO | S - Sale+OE | $45.29 | -40.0K | 0 | -100% | -$1.81M |
| D | 2024-01-08 | 2024-01-04 | KROS | Regnante Keith | CFO | M - OptEx | $0.00 | -40.0K | 53.6K | -43% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-04 | M | A | 40,000 | $16.00 | 40,000 | D | — | — | |
| 2 | Common | Common Stock | 2023-11-04 | S | D | 40,000 | $45.29 | 0 | D | — | — | |
| 3 | Derivative | Employee Stock Option (right to buy) | 2024-01-04 | M | D | 40,000 | $0.00 | 53,622 | D | $16.00 · — to 2030-04-06 | 40,000 Common Stock | (F2) One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |